Impaired cellular differentiation is a core feature of myeloid malignancies. The BRG1/Brahma-associated factor (BAF) chromatin remodeling complex, through its ATPases SMARCA4 and SMARCA2, supports leukemic blast stemness and is therefore a candidate target for differentiation-based therapy. In a phase 1 clinical study of patients with advanced myeloid malignancies, the first-in-class dual SMARCA4/2 inhibitor FHD-286 was evaluated alone and in combination with decitabine (DAC). The combination was reported to be tolerated and produced an objective response rate of 12.8% (6/47), whereas FHD-286 monotherapy produced no objective responses in the study cohort.
This preprint integrates clinical observations with high-dimensional cellular and genomic analyses to interrogate how FHD-286, alone and combined with DAC, affects tumor cell state and differentiation as a mechanism of response.
To probe mechanisms, investigators collected longitudinal bone marrow samples from both responders and nonresponders. Analyses included high-dimensional flow cytometry to resolve immunophenotypic cell states and single-cell genomic profiling to resolve transcriptional programs and clonal behavior at single-cell resolution. These approaches enabled mapping of cellular differentiation trajectories and assessment of how tumor clones moved between transcriptional and immunophenotypic compartments over time.
When administered as monotherapy, FHD-286 was predominantly associated with induction of myeloid differentiation phenotypes. The preprint reports that FHD-286 alone drove changes consistent with myeloid lineage maturation, as captured by immunophenotypic shifts in flow cytometry and transcriptional changes at the single-cell level. Despite these differentiation effects, no objective clinical responses were recorded with FHD-286 alone in the phase 1 cohort described.
In contrast to monotherapy, patients who responded to the FHD-286+DAC combination exhibited a broader set of differentiation outcomes. Responders showed a range of differentiation trajectories that included not only myeloid but also erythroid lineage programs. The combination treatment drove tumor clones to progress beyond the immunophenotypically and transcriptionally defined blast compartment to more differentiated states, consistent with terminal maturation rather than partial phenotypic shifts.
This movement of clones out of the blast compartment was observed through paired longitudinal sampling, indicating that the combination therapy altered both cell-surface phenotype and underlying transcriptional identity of malignant cells.
The preprint emphasizes that FHD-286 potentiated the transcriptional effects of decitabine, amplifying DAC-driven changes in gene expression. This potentiation appeared to facilitate full differentiation of tumor clones, suggesting a cooperative interaction in which inhibition of SMARCA4/2 chromatin remodeling modulates the transcriptional landscape established by hypomethylating therapy. As reported, the combined pharmacologic perturbation produced deeper exit of malignant cells from the blast state than either agent alone.
Responders to the combination therapy had a baseline transcriptional profile similar to that observed in CEBPA-mutant acute myeloid leukemia. During treatment, these responders exhibited further downregulation of CEBPA. The authors interpret this as evidence that preexisting transcriptional programs related to CEBPA biology may sensitize tumors to SMARCA4/2 inhibition combined with hypomethylating therapy, and that modulation of CEBPA-associated pathways is associated with clinical response in this dataset.
These results reinforce tumor cell differentiation as an on-target mechanism of response to pharmacologic inhibition of SMARCA4/2 and provide rationale to further evaluate the FHD-286+decitabine combination in molecularly defined patient subsets. The phase 1 report documents tolerability and a 12.8% objective response rate for the combination versus no responses with FHD-286 monotherapy within the studied cohort (6/47 responders).
The preprint notes trial registration (NCT04891757) and lists institutional ethical approvals. It also discloses multiple competing interests, including employment and stock relationships with Foghorn Therapeutics, and funding from Foghorn Therapeutics.
Limitations reported or implied in the preprint include that the report is a clinical preprint and has not undergone peer review; additional methodological details, comprehensive datasets, and longer-term outcomes beyond the phase 1 data were not fully reported in the source text. The findings therefore support further investigation in larger and molecularly stratified cohorts to validate the mechanistic links and clinical benefit of the combination therapy.